Incorporation of Id3 enhances CAR T cell therapeutic efficacy against solid tumors in an immunocompetent murine model

Steven James Reed,Samantha J Tower,Meenakshi Dunga,Ryma Toumi,Vandana Kalia,Surojit Sarkar

DOI: https://doi.org/10.4049/jimmunol.208.supp.117.09

2022-05-01

The Journal of Immunology

Abstract:Abstract T cell exhaustion in the tumor microenvironment (TME) has hindered the success of T cell-based immunotherapy against multiple types of solid tumors. To combat this exhaustion, we have engineered a CD19-targeted fourth generation CAR construct to express the pro-memory transcription factor Inhibitor of DNA Binding 3 (Id3). Id3 critical for the formation of long-lived memory T cells in viral infection models, and retrovirally-induced expression of Id3 in T cells has been shown to enhance the survival of effector T cells in both acute infection and tumor models.Using an immunocompetent murine model of syngeneic solid tumors expressing truncated human-CD19 (hCD19t), we demonstrate that ectopic expression of Id3 via 4th generation CARs containing Id3 (Id3-CAR) augments CAR T cell therapeutic efficacy against solid tumors. Amongst cells recovered from established solid tumors, Id3-CAR T cells retained a memory-precursor effector cell (MPEC) like phenotype including elevated expression of TCF-1, while the 3rd generation CAR T cells largely displayed a terminally exhausted (TEx) phenotype. Importantly, the inclusion of Id3 did not compromise CAR T cell proliferation or expression of the effector cytokines IFN-γ and TNFα following restimulation. In addition to superior control of primary tumors, the Id3-CAR T cells instilled greater long-term protection from tumor relapse in mice, which cleared primary tumors (6/7) compared to 3rd generation CAR T cells (3/7). Highlighting Id3 as a candidate, these data present incorporation of pro-memory transcription factors as an attractive engineering strategy to intrinsically combat CAR T cell exhaustion in the TME and promote long-term CAR T cell memory and protection from tumor relapse. Research reported in this publication was supported by the National Cancer Institute of the National Institutes of Health under Award Number F32CA265056, and Pediatric Cancer Research Foundation.

immunology